Hyperactivity Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hyperactivity Disorder stocks.

Hyperactivity Disorder Stocks Recent News

Date Stock Title
Jul 3 LLY Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
Jul 3 LLY S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
Jul 3 LLY Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Jul 3 LLY Weight-loss drugs linked to rare vision loss: Harvard study
Jul 3 LLY ADP jobs data, Constellation Brands, summer gas prices: Morning Brief
Jul 3 LLY Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
Jul 3 LLY FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
Jul 3 LLY Top 3 Health Care Stocks That May Crash This Quarter
Jul 3 LLY Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Jul 3 LLY 5 Things to Know Before the Stock Market Opens
Jul 3 LLY Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval
Jul 3 LLY Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
Jul 3 LLY Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today
Jul 2 LLY Boeing, Tesla stock reaction, small-cap portfolio: Market Domination
Jul 2 LLY Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease
Jul 2 LLY Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
Jul 2 LLY Alzheimer’s Disease Treatments: What to Know About New and Future Drugs
Jul 2 LLY Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug
Jul 2 LLY Eli Lilly Gets FDA Approval for Alzheimer's Disease Drug
Jul 2 LLY Biden, Sanders call for obesity drug makers to cut prices
Hyperactivity Disorder

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags